Sabine Luik, MD, MBA has been our Chief Medical Officer (CMO) since 2018. She reports directly to the Chief Scientific Officer.
Throughout her time with GSK, her leadership has ensured our regulatory, quality, safety, medical affairs and value evidence and outcomes teams, as well as development groups in China and Japan, work together to successfully achieve our ambitions for patients.
The organisation of the CMO, including Global Regulatory, Safety & Quality, is responsible for benefit-risk decision making for pipeline and marketed medicines and vaccines, Safety and Pharmacovigilance, Epidemiology, Bioethics, Medical Governance, Regulatory Policy, Quality and risk management (including data governance).
Across her organisation, her teams are driven by delivering what matters better and faster, always in the right way, for patients around the world.
Success in medicine development is directly tied to applying diverse views to problem solving. At GSK we constantly work to ensure clinical trial participants are representative of the patient populations affected by the diseases we aim to treat. Trials that reflect the true diversity of the population impacted by a disease – for example a women’s health issue – will lead to better insights in the development of a medicine and how it is prescribed for patients.